MedTrace Logo

Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy

NCT02770261 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2016-12-26

No results posted yet for this study

Summary

The purpose of this study is to determine superiority of DP-R208 compare to each monotherapy in patient with hypertension and primary hypercholesterolemia.

Conditions

Interventions

DRUG

DP-R208

DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo

DRUG

Candesartan32mg

DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo

DRUG

Rosuvastatin 20mg

DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg

DRUG

DP-R208 Placebo

DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg

DRUG

Candesartan32mg Placebo

DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg

DRUG

Rosuvastatin 20mg Placebo

DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo

Sponsors & Collaborators

  • Alvogen Korea

    lead INDUSTRY

Principal Investigators

  • Changkyu Park · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-08-31
Completion
2016-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02770261 on ClinicalTrials.gov